⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

March 15, 2020The Journal of Rheumatology

Rituximab and Cyclophosphamide in Antisynthetase Syndrome–related Interstitial Lung Disease: An Observational Retrospective Study

View Full Paper

Ask AI

Bookmark

Share

Abstract

Despite similar PFS at 6 months, RTX was associated with a better 2-year PFS compared to CYC in patients with AS-related ILD.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Langlois et al. (2020) studied this question.

synapsesocial.com/papers/69de9454741e97d2d4e93e65 https://doi.org/10.3899/jrheum.190505

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositisRetrospective Study · 2003 · 260 citations
2Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: A randomized, placebo‐phase trialRCT · 2012 · 700 citations
3Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels.guideline · 1974 · 1,476 citations
4Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung diseaseCohort Study · 2015 · 210 citations
5Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case ReviewRetrospective Study · 2018 · 101 citations